I know I (likely everyone) took a deep look at the onset at both opportunities. It is clear to me that the best for this drug is current management who will bring the most opportunity in favour of the drug’s future and the shareholders of this company. I absolutely saw the difference and have made an educated decision based on all of the facts not blind faith as you appear to suggest. Now do YOU see the difference?

I respectfully suggest you take this bark up another group of trees.